Previous 10 | Next 10 |
The Center for Breakthrough Medicines (CBM) Strikes Multi-Year Deal with UK Cell Therapy Powerhouse PR Newswire Strategic Partnership to Deliver US Based Manufacturing Capacity for Novel Cell Therapy KING OF PRUSSIA, Pa. , April 12, 2022 /PRNewswire/ ...
LONDON, April 05, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that management will be taking part in the following conferences in April. Acc...
- Webcast will feature Professor Charles Swanton, TRACERx Chief Investigator and Achilles co-founder - - Panel will discuss how TRACERx real-world data enable Achilles’ AI-powered PELEUS bioinformatics platform to identify and validate clonal neoantigens as targets for personaliz...
LONDON, March 08, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced its participation in the 32nd Annual Oppenheimer Healthcare Conference taking place vi...
PHILADELPHIA, March 01, 2022 (GLOBE NEWSWIRE) -- Netrality announced today that Achilles Therapeutics plc [NASDAQ: ACHL], a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, has leased 7,243 SF of lab space at 401 North Broad. Ac...
Achilles Therapeutics press release (NASDAQ:ACHL): Q4 GAAP EPS of -$0.45 beats by $0.31. Cash and cash equivalents were $266.3 million as of December 31, 2021, as compared to $177.8 million as of December 31, 2020. For further details see: Achilles Therapeutics GAAP EPS of -$0.45 b...
- Patient data from higher dose cNeT as monotherapy and cNeT in combination with checkpoint inhibitor expected in 2H 2022 - - Strong cash position of $266 million supports clinical development and manufacturing expansion into 2H 2024 - LONDON, March 01, 2022 (GLOBE NEWSWIRE...
LONDON, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced the appointment of Alena Gros, Ph.D. and Ben Creelan, M.D. to its Scientific Advisory B...
LONDON, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announces a business update and reflects on recent progress with its pioneering, personalized T c...
LONDON, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that Iraj Ali, Chief Executive Officer, will present at the virtual 40th Annual J.P. Mo...
News, Short Squeeze, Breakout and More Instantly...
Achilles Therapeutics plc Company Name:
ACHL Stock Symbol:
NASDAQ Market:
Achilles Therapeutics plc Website:
Combines Achilles’ best-in-class AI-driven, tumor-targeting technology with Arcturus’ world-leading self-amplifying mRNA platform Combined technologies have the potential to generate potent and durable T cell responses in pre-clinical IND-enabling studies LONDON, May...
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...